Further efforts, such as colitis models under gnotobiotic conditions with defined microbial backgrounds and microbiome transplantations, induced conditional DUOX2 inactivation, e.g., via switchable CRE recombinases or pre-/probiotic supplementations and interference experiments, are needed to delineate the precise molecular framework of microbial control of DUOX2 expression and the feedback regulation on the mucosal microbiome function, to enable then the development of novel therapeutic strategies for the treatment of intestinal inflammation. This evidence concerns the gene DUOX2 and gastroenteritis.